Aethlon Medical To Host Third Quarter Fiscal 2016 Investor Call on February 4, 2016

SAN DIEGO, Jan. 29, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that it will host its Third Quarter Fiscal 2016 investor conference call and webcast on Thursday, February 4, 2016 at 4:30 p.m. Eastern Time.

Aethlon Hemopurifier. (PRNewsFoto/Aethlon Medical, Inc.)

The call and webcast will follow the release of fiscal 2016 third quarter results.  A recorded version of the call will be available approximately two hours after the call at the Investor Relations portion of the company's website,

Interested parties can also access the archived replay of Aethlon Medical's Second Quarter Fiscal 2016 investor conference call webcast at in the investor relations section under events & presentations.

Conference Call Details

What: Aethlon's Third Quarter Fiscal 2016 Investor Conference Call and Webcast

Date: Thursday, February 4, 2016

Time: 4:30 p.m. Eastern Time

Live call: 412-317-5442

International: 844-836-8741

Audio Replay: 412-317-0088

Passcode: 10080270

About Aethlon Medical, Inc.

Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. The Aethlon Hemopurifier® is a leading broad-spectrum treatment countermeasure against infectious viral pathogens.  The device, which has been successfully administered to individuals infected with HIV, Hepatitis C (HCV) and Ebola virus, is currently the subject of FDA approved clinical studies. Aethlon is also studying the potential use of the Hemopurifier® to address exosomes secreted by tumors to promote the spread of metastasis and suppress the immune system of cancer patients.  The Company provides government contracting services to the Defense Advanced Research Projects Agency (DARPA) related to the development of a biofiltration device to treat sepsis and maintains majority ownership of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor Chronic Traumatic Encephalopathy (CTE) and other neurological disorders.  Additional information can be found online at or you can connect with us on Twitter, LinkedIn, Facebook and Google+.


James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000

Jim Frakes
Chief Financial Officer
858.459.7800 x300

Mike Smargiassi/Brad Edwards
Brainerd Communicators, Inc

Photo - 


To view the original version on PR Newswire, visit:

SOURCE Aethlon Medical, Inc.